ASCO® 2022

Presentation Times

Session Info Card

Seagen Development Pipeline

Seagen Development Pipeline

Brentuximab Vedotin | DLBCL | Abstract #7559

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study

Brentuximab Vedotin | cHL | Abstract #7503

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1

Enfotumab Vedotin | Urothelial Carcinoma | Abstract #4516

Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Enfortumab Vedotin | Bladder Cancer | Abstract #4582

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible

Urothelial Carcinoma | Abstract #4575

Benchmarking Maintenance Therapy Survival in First-Line Advanced Urothelial Carcinoma Using Disease Modeling

Urothelial Carcinoma | Abstract #4565

Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma

Tisotumab Vedotin | Cervical Cancer | Abstract #5507

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205

Tisotumab Vedotin | Cervical Cancer | Abstract #TPS5603

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)

Tisotumab Vedotin | Solid Tumors | Abstract #TPS6100

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors

Cervical Cancer | Abstract #5532

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis

Cervical Cancer | Abstract #5523

Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer

Tucatinib | Breast Cancer | Abstract #1108

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Tucatinib | Breast Cancer | Abstract #1111

Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress)

Ladiratuzumab Vedotin | Breast Cancer | Abstract #TPS1127

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

SGN-ALPV | Solid Tumors | Abstract #TPS3159

Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)

SGN-B7H4V | Solid Tumors | Abstract #TPS3155

Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress)

SGN-PDL1V | Solid Tumors | Abstract #TPS3154

Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress)